secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058186
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed
--------------------------------------------------------------------------------

- Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.
- Cash & investments $104.9M at March 31; April IPO grossed $100M from 6.25M shares, extending runway into 2H 2026.
- BBI-355 POTENTIATE trial advanced to Part 2 combining with EGFR or FGFR inhibitors in oncogene-amplified tumors.
- First patient dosed in BBI-825 Phase 1/2 STARMAP trial targeting resistance gene amplifications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/0000950170-24-058186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/bold-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer